(1) Medina, R. A.; Goeger, D. E.; Hills, P.; Mooberry, S. L.; Huang,
N.; Romero, L. I.; Ortega-Barría, E.; Gerwick, W. H.; McPhail, K. L.
Coibamide A, a potent antiproliferative cyclic depsipeptide from the
Panamanian marine cyanobacterium Leptolyngbya sp. J. Am. Chem.
Soc. 2008, 130, 6324−6325.
(2) Yao, G.; Pan, Z.; Wu, C.; Wang, W.; Fang, L.; Su, W. Efficient
synthesis and stereochemical revision of coibamide A. J. Am. Chem.
Soc. 2015, 137, 13488−13491.
(3) Hau, A. M.; Greenwood, J. A.; Löhr, C. V.; Serrill, J. D.; Proteau,
P. J.; Ganley, I. G.; McPhail, K. L.; Ishmael, J. E. Coibamide A induces
mTOR-independent autophagy and cell death in human glioblastoma
cells. PLoS One 2013, 8, e65250.
(4) Wan, X.; Serrill, J. D.; Humphreys, I. R.; Tan, M.; McPhail, K. L.;
Ganley, I. G.; Ishmael, J. E. ATG5 promotes death signaling in
response to the cyclic depsipeptides coibamide A and apratoxin A.
Mar. Drugs 2018, 16, 77.
(5) Shi, W.; Lu, D.; Wu, C.; Li, M.; Ding, Z.; Li, Y.; Chen, B.; Lin,
X.; Su, W.; Shao, X.; Xia, Z.; Fang, L.; Liu, K.; Li, H. Coibamide A
kills cancer cells through inhibiting autophagy. Biochem. Biophys. Res.
Commun. 2021, 547, 52−58.
(6) Serrill, J. D.; Wan, X.; Hau, A. M.; Jang, H. S.; Coleman, D. J.;
Indra, A. K.; Alani, A. W. G.; McPhail, K. L.; Ishmael, J. E. Coibamide
A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression
and suppresses tumor growth in glioblastoma xenografts. Invest. New
Drugs 2016, 34, 24−40.
(7) Kazemi, S.; Kawaguchi, S.; Badr, C. E.; Mattos, D. R.; RuizSaenz, A.; Serrill, J. D.; Moasser, M. M.; Dolan, B. P.; Paavilainen, V.
O.; Oishi, S.; McPhail, K. L.; Ishmael, J. E. Targeting of HER/ErbB
family proteins using broad spectrum Sec61 inhibitors coibamide A
and apratoxin A. Biochem. Pharmacol. 2021, 183, 114317.
(8) Tranter, D.; Paatero, A. O.; Kawaguchi, S.; Kazemi, S.; Serrill, J.
D.; Kellosalo, J.; Vogel, W. K.; Richter, U.; Mattos, D. R.; Wan, X.;
Thornburg, C. C.; Oishi, S.; McPhail, K. L.; Ishmael, J. E.;
Paavilainen, V. O. Coibamide A targets Sec61 to prevent biogenesis
of secretory and membrane proteins. ACS Chem. Biol. 2020, 15,
2125−2136.
(9) Lang, S.; Pfeffer, S.; Lee, P. H.; Cavalié, A.; Helms, V.; Förster,
F.; Zimmermann, R. An update on Sec61 channel functions,
mechanisms, and related diseases. Front. Physiol. 2017, 8, 887.
(10) Sicking, M.; Lang, S.; Bochen, F.; Roos, A.; Drenth, J. P. H.;
Zakaria, M.; Zimmermann, R.; Linxweiler, M. Complexity and
specificity of Sec61-channelopathies: human diseases affecting gating
of the Sec61 complex. Cells 2021, 10, 1036.
(11) Linxweiler, M.; Schick, B.; Zimmermann, R. Let’s talk about
Secs: Sec61, Sec62 and Sec63 in signal transduction, oncology and
personalized medicine. Signal Transduct. Target Ther. 2017, 2, e17002.
(12) O’Keefe, S.; Roboti, P.; Duah, K. B.; Zong, G.; Schneider, H.;
Shi, W. Q.; High, S. Ipomoeassin-F inhibits the in vitro biogenesis of
the SARS-CoV-2 spike protein and its host cell membrane receptor. J.
Cell Sci. 2021, 134, jcs257758.
(13) Van Puyenbroeck, V.; Vermeire, K. Inhibitors of protein
translocation across membranes of the secretory pathway: novel
antimicrobial and anticancer agents. Cell. Mol. Life Sci. 2018, 75,
1541−1558.
(14) Luesch, H.; Paavilainen, V. O. Natural products as modulators
of eukaryotic protein secretion. Nat. Prod. Rep. 2020, 37, 717−736.
AUTHOR INFORMATION
Corresponding Author
Shinya Oishi − Graduate School of Pharmaceutical Sciences,
Kyoto University, Kyoto 606-8501, Japan; Department of
Medicinal Chemistry, Kyoto Pharmaceutical University,
Kyoto 607-8412, Japan; orcid.org/0000-0002-28332539; Email: soishi@mb.kyoto-phu.ac.jp
Authors
Takashi Kitamura − Graduate School of Pharmaceutical
Sciences, Kyoto University, Kyoto 606-8501, Japan
Rikito Suzuki − Graduate School of Pharmaceutical Sciences,
Kyoto University, Kyoto 606-8501, Japan; Department of
Medicinal Chemistry, Kyoto Pharmaceutical University,
Kyoto 607-8412, Japan
Shinsuke Inuki − Graduate School of Pharmaceutical Sciences,
Kyoto University, Kyoto 606-8501, Japan; orcid.org/
0000-0002-7525-1280
Hiroaki Ohno − Graduate School of Pharmaceutical Sciences,
Kyoto University, Kyoto 606-8501, Japan
Kerry L. McPhail − Department of Pharmaceutical Sciences,
College of Pharmacy, Oregon State University, Corvallis,
Oregon 97331, United States; orcid.org/0000-00032076-1002
Complete contact information is available at:
https://pubs.acs.org/10.1021/acsmedchemlett.1c00591
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
This work was supported by the NIGMS (R01GM132649),
AMED (JP18lm0203006j0002 and JP19am0101092j0003),
and the Takeda Science Foundation.
ABBREVIATIONS
Alloc, allyloxycarbonyl; ATG5, authophagy-related protein 5;
Bph, β-(4-biphenylyl)alanine; DIC, N,N′-diisopropylcarbodiimide; DIEA, N,N-diisopropylethylamine; EDCI, 1-ethyl-3-(3(dimethylamino)propyl)carbodiimide; EGFR, epidermal
growth factor receptor; HATU, O-(7-aza-1H-benzotriazol-1yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate;
HFIP, 1,1,1,3,3,3-hexafluoro-2-propanol; Hva, 2-hydroxyisovaleric acid; HOAt, 1-hydroxy-7-azabenzotriazole; HOBt, 1hydroxybenzotriazole; Me2Val, N,N-dimethylvaline; MeAla, Nmethylalanine; MeIle, N-methylisoleucine; MeLeu, N-methylleucine; MeLys, Nα-methyllysine; MeLys(Me), N,N′-dimethyl109
https://doi.org/10.1021/acsmedchemlett.1c00591
ACS Med. Chem. Lett. 2022, 13, 105−110
A Self-archived copy in
Kyoto University Research Information Repository
https://repository.kulib.kyoto-u.ac.jp
ACS Medicinal Chemistry Letters
pubs.acs.org/acsmedchemlett
(15) Huang, K.-C.; Chen, Z.; Jiang, Y.; Akare, S.; Kolber-Simonds,
D.; Condon, K.; Agoulnik, S.; Tendyke, K.; Shen, Y.; Wu, K.-M.;
Mathieu, S.; Choi, H.-w.; Zhu, X.; Shimizu, H.; Kotake, Y.; Gerwick,
W. H.; Uenaka, T.; Woodall-Jappe, M.; Nomoto, K. Apratoxin A
shows novel pancreas-targeting activity through the binding of Sec61.
Mol. Cancer Ther. 2016, 15, 1208−1216.
(16) Paatero, A. O.; Kellosalo, J.; Dunyak, B. M.; Almaliti, J.;
Gestwicki, J. E.; Gerwick, W. H.; Taunton, J.; Paavilainen, V. O.
Apratoxin kills cells by direct blockade of the Sec61 protein
translocation channel. Cell Chem. Biol. 2016, 23, 561−566.
(17) Junne, T.; Wong, J.; Studer, C.; Aust, T.; Bauer, B. W.; Beibel,
M.; Bhullar, B.; Bruccoleri, R.; Eichenberger, J.; Estoppey, D.;
Hartmann, N.; Knapp, B.; Krastel, P.; Melin, N.; Oakeley, E. J.;
Oberer, L.; Riedl, R.; Roma, G.; Schuierer, S.; Petersen, F.; Tallarico,
J. A.; Rapoport, T. A.; Spiess, M.; Hoepfner, D. Decatransin, a new
natural product inhibiting protein translocation at the Sec61/SecYEG
translocon. J. Cell Sci. 2015, 128, 1217−1229.
(18) Cross, B. C. S.; McKibbin, C.; Callan, A. C.; Roboti, P.;
Piacenti, M.; Rabu, C.; Wilson, C. M.; Whitehead, R.; Flitsch, S. L.;
Pool, M. R.; High, S.; Swanton, E. Eeyarestatin I inhibits Sec61mediated protein translocation at the endoplasmic reticulum. J. Cell
Sci. 2009, 122, 4393−4400.
(19) Gamayun, I.; O’Keefe, S.; Pick, T.; Klein, M.-C.; Nguyen, D.;
McKibbin, C.; Piacenti, M.; Williams, H. M.; Flitsch, S. L.;
Whitehead, R. C.; Swanton, E.; Helms, V.; High, S.; Zimmermann,
R.; Cavalié, A. Eeyarestatin compounds selectively enhance Sec61mediated Ca2+ leakage from the endoplasmic reticulum. Cell Chem.
Biol. 2019, 26, 571−583.
(20) Besemer, J.; Harant, H.; Wang, S.; Oberhauser, B.; Marquardt,
K.; Foster, C. A.; Schreiner, E. P.; de Vries, J. E.; Dascher-Nadel, C.;
Lindley, I. J. D. Selective inhibition of cotranslational translocation of
vascular cell adhesion molecule 1. Nature 2005, 436, 290−293.
(21) Garrison, J. L.; Kunkel, E. J.; Hegde, R. S.; Taunton, J. A
substrate-specific inhibitor of protein translocation into the
endoplasmic reticulum. Nature 2005, 436, 285−289.
(22) MacKinnon, A. L.; Garrison, J. L.; Hegde, R. S.; Taunton, J.
Photo-leucine incorporation reveals the target of a cyclodepsipeptide
inhibitor of cotranslational translocation. J. Am. Chem. Soc. 2007, 129,
14560−14561.
(23) Zong, G.; Hu, Z.; O’Keefe, S.; Tranter, D.; Iannotti, M. J.;
Baron, L.; Hall, B.; Corfield, K.; Paatero, A. O.; Henderson, M. J.;
Roboti, P.; Zhou, J.; Sun, X.; Govindarajan, M.; Rohde, J. M.;
Blanchard, N.; Simmonds, R.; Inglese, J.; Du, Y.; Demangel, C.; High,
S.; Paavilainen, V. O.; Shi, W. Q. Ipomoeassin F binds Sec61α to
inhibit protein translocation. J. Am. Chem. Soc. 2019, 141, 8450−
8461.
(24) Baron, L.; Paatero, A. O.; Morel, J.-D.; Impens, F.; GueninMacé, L.; Saint-Auret, S.; Blanchard, N.; Dillmann, R.; Niang, F.;
Pellegrini, S.; Taunton, J.; Paavilainen, V. O.; Demangel, C.
Mycolactone subverts immunity by selectively blocking the Sec61
translocon. J. Exp. Med. 2016, 213, 2885−2896.
(25) Chen, Y.; Bilban, M.; Foster, C. A.; Boger, D. L. Solution-phase
parallel synthesis of a pharmacophore library of HUN-7293
analogues: a general chemical mutagenesis approach to defining
structure-function properties of naturally occurring cyclic (depsi)peptides. J. Am. Chem. Soc. 2002, 124, 5431−5440.
(26) Ding, R.; Zhang, T.; Xie, J.; Williams, J.; Ye, Y.; Chen, L.
Eeyarestatin I derivatives with improved aqueous solubility. Bioorg.
Med. Chem. Lett. 2016, 26, 5177−5181.
(27) Onda, Y.; Masuda, Y.; Yoshida, M.; Doi, T. Conformationbased design and synthesis of apratoxin A mimetics modified at the
α,β-unsaturated thiazoline moiety. J. Med. Chem. 2017, 60, 6751−
6765.
(28) Yao, G.; Wang, W.; Ao, L.; Cheng, Z.; Wu, C.; Pan, Z.; Liu, K.;
Li, H.; Su, W.; Fang, L. Improved total synthesis and biological
evaluation of coibamide A analogues. J. Med. Chem. 2018, 61, 8908−
8916.
(29) Gehringer, M.; Mäder, P.; Gersbach, P.; Pfeiffer, B.; Scherr, N.;
Dangy, J. P.; Pluschke, G.; Altmann, K.-H. Configurationally stabilized
Letter
analogs of M. ulcerans exotoxins mycolactones A and B reveal the
importance of side chain geometry for mycolactone virulence. Org.
Lett. 2019, 21, 5853−5857.
(30) Zong, G.; Hu, Z.; Duah, K. B.; Andrews, L. E.; Zhou, J.;
O’Keefe, S.; Whisenhunt, L.; Shim, J. S.; Du, Y.; High, S.; Shi, W. Q.
Ring expansion leads to a more potent analogue of ipomoeassin F. J.
Org. Chem. 2020, 85, 16226−16235.
(31) Wu, C.; Cheng, Z.; Lu, D.; Liu, K.; Cheng, Y.; Wang, P.; Zhou,
Y.; Li, M.; Shao, X.; Li, H.; Su, W.; Fang, L. Novel N-methylated
cyclodepsipeptide prodrugs for targeted cancer therapy. J. Med. Chem.
2021, 64, 991−1000.
(32) Nabika, R.; Suyama, T. L.; Hau, A. M.; Misu, R.; Ohno, H.;
Ishmael, J. E.; McPhail, K. L.; Oishi, S.; Fujii, N. Synthesis and
biological evaluation of the [D-MeAla11]-epimer of coibamide A.
Bioorg. Med. Chem. Lett. 2015, 25, 302−306.
(33) Biron, E.; Chatterjee, J.; Kessler, H. Optimized selective Nmethylation of peptides on solid support. J. Pept. Sci. 2006, 12, 213−
219.
(34) Kelly, C. N.; Townsend, C. E.; Jain, A. N.; Naylor, M. R.; Pye,
C. R.; Schwochert, J.; Lokey, R. S. Geometrically diverse lariat peptide
scaffolds reveal an untapped chemical space of high membrane
permeability. J. Am. Chem. Soc. 2021, 143, 705−714.
(35) Chen, Q.-Y.; Liu, Y.; Luesch, H. Systematic chemical
mutagenesis identifies a potent novel apratoxin A/E hybrid with
improved in vivo antitumor activity. ACS Med. Chem. Lett. 2011, 2,
861−865.
Recommended by ACS
Potent Bactericidal Antimycobacterials Targeting the
Chaperone ClpC1 Based on the Depsipeptide Natural
Products Ecumicin and Ohmyungsamycin A
Paige M. E. Hawkins, Richard J. Payne, et al.
MARCH 16, 2022
JOURNAL OF MEDICINAL CHEMISTRY
READ
Discovery and Development of Cyclic Peptide Inhibitors
of CIB1
Victoria A. Haberman, Albert A. Bowers, et al.
OCTOBER 27, 2021
ACS MEDICINAL CHEMISTRY LETTERS
READ
High-Resolution Structure of ClpC1-Rufomycin and
Ligand Binding Studies Provide a Framework to Design
and Optimize Anti-Tuberculosis Leads
Nina M. Wolf, Sanghyun Cho, et al.
APRIL 16, 2019
ACS INFECTIOUS DISEASES
READ
Synthetic Sansanmycin Analogues as Potent
Mycobacterium tuberculosis Translocase I Inhibitors
Wendy Tran, Richard J. Payne, et al.
NOVEMBER 30, 2021
JOURNAL OF MEDICINAL CHEMISTRY
READ
Get More Suggestions >
110
https://doi.org/10.1021/acsmedchemlett.1c00591
ACS Med. Chem. Lett. 2022, 13, 105−110
...
論文の公開元へ
